See more : Paris Miki Holdings Inc. (7455.T) Income Statement Analysis – Financial Results
Complete financial analysis of Biotricity, Inc. (BTCY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biotricity, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Camplify Holdings Limited (CHL.AX) Income Statement Analysis – Financial Results
- China Finance Online Co. Limited (JRJC) Income Statement Analysis – Financial Results
- Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) Income Statement Analysis – Financial Results
- China Tianrui Automotive Interiors Co., LTD (6162.HK) Income Statement Analysis – Financial Results
- SOHM, Inc. (SHMN) Income Statement Analysis – Financial Results
Biotricity, Inc. (BTCY)
About Biotricity, Inc.
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06M | 9.64M | 7.65M | 3.38M | 1.42M | 398.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.71M | 4.20M | 3.08M | 2.11M | 931.95K | 338.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 8.36M | 5.44M | 4.57M | 1.27M | 485.77K | 59.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 69.27% | 56.46% | 59.74% | 37.60% | 34.26% | 15.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.57M | 3.23M | 2.74M | 2.06M | 1.36M | 1.31M | 1.76M | 1.14M | 1.14M | 23.20K | 53.60K |
| General & Administrative | 14.61M | 17.62M | 18.56M | 12.57M | 10.05M | 7.34M | 5.96M | 4.80M | 3.99M | 56.09K | 29.25K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.61M | 17.62M | 18.56M | 12.57M | 10.05M | 7.34M | 5.96M | 4.80M | 3.99M | 56.09K | 29.25K |
| Other Expenses | 0.00 | -181.94K | -1.14M | -67.10K | 16.94K | 0.00 | 0.00 | 0.00 | 0.00 | -1.22K | -1.15K |
| Operating Expenses | 17.18M | 20.85M | 21.31M | 14.62M | 11.42M | 8.65M | 7.72M | 5.94M | 5.13M | 89.60K | 89.92K |
| Cost & Expenses | 20.89M | 25.05M | 24.39M | 16.74M | 12.35M | 8.99M | 7.72M | 5.94M | 5.13M | 89.60K | 89.92K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.19M | 2.58M | 10.57M | 2.48M | 92.42K | 0.00 | 879.42K | 1.18M | 59.88K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.95K | 346.26K | 68.34K | 347.12K | 148.76K | 8.58M | 7.72M | 5.94M | 9.05K | 810.00 | 1.15K |
| EBITDA | -8.90M | -15.40M | -18.02M | -13.35M | -10.93M | -8.59M | 0.00 | -5.94M | -5.12M | 0.00 | -89.92K |
| EBITDA Ratio | -73.75% | -161.69% | -233.65% | -396.45% | -769.81% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.83M | -15.59M | -17.88M | -13.42M | -10.91M | -8.59M | -7.72M | -5.94M | -5.13M | -90.41K | -91.07K |
| Operating Income Ratio | -73.18% | -161.75% | -233.68% | -396.45% | -769.81% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.27M | -3.25M | -12.39M | -2.78M | -136.26K | 0.00 | -900.00K | -1.87M | -55.85K | 7.00 | 0.00 |
| Income Before Tax | -14.09M | -18.66M | -29.13M | -15.49M | -11.07M | -8.59M | -8.62M | -7.81M | -5.19M | -90.81K | -91.07K |
| Income Before Tax Ratio | -116.84% | -193.57% | -380.78% | -457.67% | -780.61% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.40M | 9.43M | 2.07M | -39.41K | -171.86K | -6.84M | -4.76M | 50.82K | -810.00 | -1.15K |
| Net Income | -14.09M | -18.66M | -29.13M | -15.49M | -11.07M | -8.59M | -8.62M | -7.81M | -5.19M | -90.81K | -91.07K |
| Net Income Ratio | -116.84% | -193.57% | -380.78% | -457.67% | -780.61% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.66 | -2.15 | -3.85 | -2.48 | -1.85 | -1.54 | -1.72 | -1.81 | -1.42 | -0.06 | -0.06 |
| EPS Diluted | -1.66 | -2.15 | -3.85 | -2.48 | -1.85 | -1.54 | -1.72 | -1.81 | -1.42 | -0.06 | -0.06 |
| Weighted Avg Shares Out | 8.99M | 8.66M | 7.57M | 6.25M | 5.99M | 5.56M | 5.03M | 4.31M | 3.64M | 1.50M | 1.50M |
| Weighted Avg Shares Out (Dil) | 8.99M | 8.66M | 7.57M | 6.25M | 5.99M | 5.56M | 5.03M | 4.31M | 3.64M | 1.50M | 1.50M |
Biotricity's (BTCY) CEO Waqaas Al-Siddiq on Q3 2022 Results - Earnings Call Transcript
Biotricity's (BTCY) CEO Waqaas Al-Siddiq on Q3 2022 Results - Earnings Call Transcript
Biotricity to Report Third Quarter Fiscal 2022 Financial Results on February 14, 2022
Management to host call on Tuesday, February 15th at 4:15pm ET Sees Calendar-2022 as a breakout year with commercial launch of Bioheart and FDA clearance for Biotres REDWOOD CITY, CA / ACCESSWIRE / February 8, 2022 / Biotricity, Inc. (NASDAQ:BTCY)...
Biotricity Delivers Bioheart, A Groundbreaking Consumer Heart Monitor
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Biotricity, Inc. (NASDAQ:BTCY), a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions, today announced the availability of Bioheart, a direct-to-consumer heart monitor that offers the same continuous heart monitoring technology used by physicians....
Biotricity's (BTCY) CEO Waqaas Al-Siddiq on Q2 2022 Results - Earnings Call Transcript
Biotricity's (BTCY) CEO Waqaas Al-Siddiq on Q2 2022 Results - Earnings Call Transcript
Biotricity to Report Second Quarter Fiscal 2022 Financial Results on November 4, 2021
Management to Host Conference Call and Live Webcast at 5pm ET REDWOOD CITY, CA / ACCESSWIRE / November 2, 2021 / Biotricity, Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will release its financial...
3 Biotech Penny Stocks to Watch That Are Climbing Right Now
Why investors are watching these biotech penny stocks right now The post 3 Biotech Penny Stocks to Watch That Are Climbing Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Biotricity to Discuss its Breakthrough Patient Monitoring Solutions at Virtual LD Micro Main Event XIV on Oct. 13th
REDWOOD CITY, CA / ACCESSWIRE / October 12, 2021 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that its Chief Executive Officer Waqaas Al Siddiq is scheduled to present in-person...
Biotricity Launches Biocare Cardiac Application for Samsung's Galaxy Watch4 Series
REDWOOD CITY, CA / ACCESSWIRE / October 7, 2021 / Biotricity Inc. (NASDAQ: BTCY), a medical diagnostic and consumer healthcare technology company, today announced the upcoming release of Biocare Cardiac - a personal, cardiac health application for individuals diagnosed with or...
Biotricity Launches Biocare Cardiac Application for Samsung's Galaxy Watch4 Series
REDWOOD CITY, CA / ACCESSWIRE / October 7, 2021 / Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the upcoming release of Biocare Cardiac - a personal, cardiac health application for individuals diagnosed with or...
Remote Medical Diagnostic Company, Biotricity, to Ring the Nasdaq Stock Market Opening Bell on Thursday, October 7th
Founder and CEO Waqaas Al Siddiq and Members of Biotricity Management Team to Attend Opening Bell Ceremony on Thursday, October 7, 2021 at 9:30am E.T. REDWOOD CITY, CA / ACCESSWIRE / October 6, 2021 / Biotricity Inc. (NASDAQ:BTCY), a medical...
Source: https://incomestatements.info
Category: Stock Reports